Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews

M Cruciani, I Pati, F Masiello, S Pupella… - Journal of …, 2024 - academic.oup.com
Objectives A reappraisal of the validity of the conclusions of systematic reviews (SRs)
related to nirmatrelvir/ritonavir for the treatment of COVID-19. Methods An overview of SRs …

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies

YM Mesfin, JE Blais, KT Kibret… - Journal of …, 2024 - academic.oup.com
Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …

[HTML][HTML] Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review

AS Cha-Silva, MB Gavaghan, T Bergroth… - American Journal of …, 2024 - journals.lww.com
Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-
moderate coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high …

[HTML][HTML] Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis

B Amani, B Amani - PloS one, 2024 - journals.plos.org
Objective The aim of this study was to assess the effectiveness and safety of azvudine in
treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory …

Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan

T Mizuno, Y Kondo, M Sakai, K Saneyasu… - Journal of Infection and …, 2024 - Elsevier
Introduction This study aimed to evaluate the cost-effectiveness of nirmatrelvir/ritonavir
(Nir/Rit) for adult outpatients with COVID-19 from the perspective of a Japanese public …